Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
News|Articles|May 4, 2026
5 FDA Decisions for Primary Care to Know from April 2026
Author(s)Sydney Jennings
Fact checked by: Abigail Brooks, MA
FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.
Advertisement
Advertisement
In April, the US Food and Drug Administration (FDA) issued several notable regulatory decisions spanning obesity management, infectious disease, rare genetic conditions, and diabetes care. The following list highlights 5 key updates for primary care, including approval of a novel oral GLP-1 receptor agonist for weight management, a new 2-drug regimen for virologically suppressed HIV, a first-in-class gene therapy for inherited hearing loss, and expanded use of automated insulin delivery technology in pregnancy.
Related to this article
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
FDA awarded DT120 Breakthrough Therapy designation for MDD based on phase 3 data showing rapid, sustained improvement after one 100 μg dose.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Advertisement
Advertisement